Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2010
04/06/2010US7691566 Compositions and methods for treatment of cancer
04/06/2010US7691421 Comprising Cucurbita moschata, Carthamus tinctorius, Plantago asiatica and Lonicera japonica; climacteric disturbance, primary hypogonadism (including ovarian hypofunction and testicular deficiency), Turner's syndrome, Klinefelter's syndrome, gonadotropin-producing tumor, testitis, ovarian amenorrhea
04/06/2010US7691393 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
04/06/2010US7691378 Treating carcinomas or adenocarcinomas using at least one anti-TNF (tumor necrosis factor) antibody
04/06/2010US7691376 monoclonal antibodies or fragment thereof which binds a cell surface glycoprotein antigen located on the surface of human multiple myeloma tumor cells; for therapeutic, screening, diagnostic and cell purification purposes
04/06/2010US7691372 contains the idiotype of the HE2 antibody directed against the cellular membrane antigen Ep-CAM
04/06/2010US7691366 Chimeric CMP-Ang1 molecule
04/06/2010CA2546192C Pyrrolopyrimidine compounds useful in treatment of cancer
04/06/2010CA2475137C New heterocyclic oxime derivatives, their preparation process and the pharmaceutical compositions that contain them
04/06/2010CA2455181C Benzimidazo[4,5-f]isoquinolinone derivatives
04/06/2010CA2453507C A controlled release biodegradable gel matrix
04/06/2010CA2416220C Preparation of phosphatase inhibitors
04/06/2010CA2361057C Quinoline derivatives and quinazoline derivatives
04/06/2010CA2358505C Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
04/06/2010CA2280930C Protein markers for lung cancer and use thereof
04/06/2010CA2193491C Replication-competent herpes simplex virus mediates destruction of neoplastic cells
04/01/2010WO2010037095A2 Agents and methods for the treatment of cancer
04/01/2010WO2010037067A1 Fused ring thiophene dyes for imaging and therapy
04/01/2010WO2010037059A2 Heteroaryl antagonists of prostaglandin d2 receptors
04/01/2010WO2010037041A2 Frizzled-binding agents and uses thereof
04/01/2010WO2010036959A2 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
04/01/2010WO2010036936A2 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
04/01/2010WO2010036928A1 Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
04/01/2010WO2010036917A1 Prevention and treatment of cancer with ras gene mutation
04/01/2010WO2010036873A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
04/01/2010WO2010036814A1 Selective seprase inhibitors
04/01/2010WO2010036796A1 Pyridineamine derivatives
04/01/2010WO2010036631A2 Compounds which selectively modulate the cb2 receptor
04/01/2010WO2010036630A2 Compounds which selectively modulate the cb2 receptor
04/01/2010WO2010036629A2 Fused multicyclic compounds as protein kinase inhibitors
04/01/2010WO2010036567A2 Harmine compounds for promoting bone growth
04/01/2010WO2010036407A2 Antiviral nucleoside analogs
04/01/2010WO2010036404A2 Novel retinamide retinoic acid metabolism blocking agents
04/01/2010WO2010036335A1 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
04/01/2010WO2010036213A1 3-deazaneplanocin derivatives
04/01/2010WO2010036140A1 Metal complexes, a method for preparing same, radiopharmaceutical means based thereon
04/01/2010WO2010035806A1 Solid pharmaceutical composition
04/01/2010WO2010035769A1 Improved antibody molecule
04/01/2010WO2010035259A2 Compositions and methods for diagnosing and treating b-cll
04/01/2010WO2010035221A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
04/01/2010WO2010035217A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
04/01/2010WO2010034838A2 New chemical compounds
04/01/2010WO2010034774A1 Compound for local deletion of tumors
04/01/2010WO2010034700A1 Treating cancer by modulating rna helicases
04/01/2010WO2010034693A1 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
04/01/2010WO2010034414A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
04/01/2010WO2010034128A1 Spy1a as a diagnostic and prognostic marker of cancer
04/01/2010WO2010017545A3 Triazole compounds that modulate hsp90 activity
04/01/2010WO2010017514A3 Methods of predicting cancer lethality using replikin counts
04/01/2010WO2010017240A3 Aurora kinase modulators and methods of use
04/01/2010WO2010012651A3 Composition useful for the prevention or reduction of the progression of prostate cancer
04/01/2010WO2010006125A3 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
04/01/2010WO2010003057A3 Treating cancer
04/01/2010WO2010002845A3 Quinazoline derivatives
04/01/2010WO2010001102A3 Photochemical internalisation of kinase inhibitors
04/01/2010WO2009151762A3 Anticancer methods using extracts of anemarrhena asphodeloides bunge
04/01/2010WO2009148654A3 Cephalotaxus esters, methods of synthesis, and uses thereof
04/01/2010WO2009143064A3 Rice bran extracts for inflammation and methods of use thereof
04/01/2010WO2009140675A3 Combination therapy with pm00104 and another antitumor agent
04/01/2010WO2009138762A3 Therapeutic use of peptides
04/01/2010WO2009094751A8 An anti-cancer cytotoxic monoclonal antibody
04/01/2010US20100081797 Manipulation of Cytokine Levels Using CD83 Gene Products
04/01/2010US20100081711 Cytotoxic agents
04/01/2010US20100081704 Modulator compounds of the drug resistance in epithelial tumour cells
04/01/2010US20100081703 Tri-demethylation-capable protein complex, method of its preparation and its use
04/01/2010US20100081678 Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
04/01/2010US20100081677 Heteroarylamide pyrimidone derivatives
04/01/2010US20100081676 Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same
04/01/2010US20100081675 Fused multicyclic compounds as protein kinase inhibitors
04/01/2010US20100081670 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
04/01/2010US20100081662 Pyrrolotriazine kinase inhibitors
04/01/2010US20100081659 Sigma receptor inhibitors
04/01/2010US20100081652 Cinnamoyl Compound and Use Thereof
04/01/2010US20100081645 Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
04/01/2010US20100081641 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
04/01/2010US20100081627 Polymeric nucleoside prodrugs
04/01/2010US20100081620 Prodomain modulators of adam 10
04/01/2010US20100081618 Transporters Comprising Spaced Arginine Moieties
04/01/2010US20100081611 Stabilized maml peptides and uses thereof
04/01/2010US20100081192 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
04/01/2010US20100081153 Cancer associated protein kinases and their uses
04/01/2010US20100080843 Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis
04/01/2010US20100080822 treating menstrual cramps by administering composition of extracts from stem of Cinnamomum cassia, sclerotium of Poria cocos, root bark of Paeonia suffruticosa, root of Paeonia lactiflora and seed of Prunus persica or Prunus davidiana; composition comprises1.3-1.9% Paeoniflorin and 0.7-1.1% Paeonol
04/01/2010US20100080819 Modulators of p-selectin glycoprotein ligand 1
04/01/2010US20100080815 MN Gene and Protein
04/01/2010US20100080808 Anti-notch2 antibodies and methods of use
04/01/2010US20100080799 Wstf regulates the dna damage response of h2a.x via novel tyrosine kinase activity
04/01/2010US20100080792 Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
04/01/2010US20100080789 Therapeutic ribonucleases
04/01/2010US20100080776 Method of enhancing an immune response
04/01/2010US20100080775 Recombinant adenoviruses encoding the specific iodine transporter (nis)
04/01/2010US20100080769 Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
04/01/2010CA2775062A1 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
04/01/2010CA2738549A1 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
04/01/2010CA2738485A1 Frizzled-binding agents and uses thereof
04/01/2010CA2738448A1 New chemical compounds
04/01/2010CA2738252A1 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
04/01/2010CA2738195A1 Spy1a as a diagnostic and prognostic marker of cancer
04/01/2010CA2738147A1 Solid pharmaceutical composition
04/01/2010CA2737941A1 Selective seprase inhibitors
1 ... 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 ... 2211